Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS-1103 in healthy volunteers
NCT06316973Phase 1Completed
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CS-1103 in methamphetamine use disorder (MUD) (5 arms). Primary endpoints: Treatment-Emergent Adverse Events at 11 days and Severity of Adverse Events at 11 days. Started Feb 2024; status: completed.
02
Drugs
CS-1103
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT06316973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316973.